Combined effect of flavonoid compounds and cytostatics in cancer treatment
DOI:
https://doi.org/10.15584/ejcem.2017.2.10Keywords:
flavonoids, anticancer drugs, co-delivery system, cytostaticsAbstract
Aim. The aim of the study was to review the literature on the combination of cytostatics with flavonoids as a promising way to improve the cancer therapy.
Material and methods. A review of Polish and foreign literature was performed. The following databases were searched: PubMed, Scopus, Science Direct, and Polish Medical Bibliography.
Literature analysis. Effective strategies to inhibit the progression of cancer are needed. Compounds of natural origin, including plant polyphenols, are a part of our diet. Due to their availability, and antioxidant properties, they may serve as efficacious adjuvants in cancer therapy, enhancing the effectiveness of chemotherapeutics. Epidemiological studies have shown an inverse relationship between diets rich in fruits, vegetables, and supplements, and the risk of all causes of death from cancer. Based on their diverse biological activity, flavonoids may be potential adjuvant therapeutic agents that act synergistically with cytostatics for treatment of many types of cancer. This review of the results is a summary the research on anticancer activity of flavonoids and may also raise consciousness of consumers, who will be able to compose their diet armed with the knowledge of preventive and therapeutic anticancer properties of food ingredients. There is need for further research on polyphenols of plant origin, including interactions among food components that coexist. Another important aspect is to understand how the activity of phytocompounds depends on concentration and the presence of additional factors (e.g. microflore, metal ions), which could possibly make a compound harmful, instead of having positive theraputics effect. Elucidation of the mechanisms involved in biological activity of the described phytocompounds is essential for a better understanding of their influence on an organism.
Downloads
References
Kang KP, Park SK, Kim DH, et al. Luteolin ameliorates cisplatin-induces acute kidney injury in mice by regulation of p53-dependent renal tubular apoptosis. Nephrol Dial Transplant. 2011;26(3):814-822.
Yuan Y, Qui C, Nicoli D, et al. Inhibition of human cytochrome P450 enzymes by hops (Humulus lupulus) and hop prenylphenols. Eur J Pharm Sci. 2014;53: 55-61.
Wang Q, Ding Z, Liu J, Zheng Y. Xanthohumol, a novel anti-HIV-1 agent purified from hops Humulus lupulus. Antivir Res. 2004;64:189–194.
Stompor M, Żarowska B. Antimicrobial activity of xanthohumol and its selected structural analogues. Molecules. 2016;21:608.
Cho Y-C, You S-K, Kim HJ, Cho C-W, Lee I-S, Kang BY. Xanthohumol inhibits IL-12 production and reduces chronic allergic contact dermatitis. Inter Immunol. 2010;10: 556-561.
Miranda CL, Stevens JF, Helmrich A, et al. Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (Humulus lupulus) in human cancer cell lines. Food Chem Toxicol. 1999;37:271-285.
Gerhauser C, Alt A, Heiss E, et al. Cancer chemopreventive activity of xanthohumol, a natural product derived from hop. Mol Cancer Ther. 2002;1(11):959-969.
Ho Y-C, Liu C-H, Chen C-N, Duan K-J, Lin M-T. Inhibitory effects of xanthohumol from hops (Humulus lupulus L.) on human hepatocellular carcinoma cell lines. Phytother Res. 2008;22(11):1465-1468.
Vanhoecke B, Derycke L, Marck VV, Depypere H, Keukeleire DD, Bracke M. Antiinvasive effect of xanthohumol, a prenylated chalcone present in hops (Humulus lupulus L.) and beer. Int J Cancer. 2005;117(6),889-895.
Monteiro R, Faria A, Azevedo I, Calhau C. Modulation of breast cancer cell survival by aromatase inhibiting hop (Humulus lupulus L.) flavonoids. J Steroid Biochem Mol Biol. 2007;105(1-5):124–130.
Morikawa K, Nonaka M, Mochizuki H, Hanada K, Hanada H, Hirota K. Naringenin and hesperetin induce growth agrest, apoptosis, and cytoplasmic fat deposit in human preadipocytes. J Agric Food Chem. 2008;26:11030-11037.
Stevens JF, Taylor AW, Clawson JE, Deinzer ML. Fate of xanthohumol and related prenylflavonoids from hops to beer. J Agric Food Chem. 1999;47(6):2421-2428.
Brunelli E, Minassi A, Appendino G, Moro L. 8-Prenylnaringenin, inhibits estrogen receptor-α mediated cell growth and induces apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2007;107: 140-148.
Chen W, Becker T, Qian F, Ring J. Beer and beer compounds: physiological effects on skin health. J Eur Acad Dermatol Venerol. 2014;28(2):142-150.
Pinho-Ribeiro FA, Zarpelon AC, Fattori V, et al. Naringenin reduces inflammatory pain in mice. Neuropharmacol. 2016;105:508-519.
Paoletti T, Fallarini S, Gugliesti F, Minassi A, Appendino G, Lombardi G. Anti-inflammatory and vascularprotective properties of 8-prenylapigenin. Eur J Pharmacol. 2009;620(1-3):120-130.
Xu X-H, Ma C-M, Han Y-Z, et al. Protective effect of naringenin on glutamate-induced neurotoxicity in cultured hippocampal cells. Arch Biol Sci. 2015;67:639-646.
Kuete V, Ango PY, Yeboah SO, et al. Cytotoxicity of four Aframomum species (A. arundinaceum, A. alboviolaceum, A. kayserianum and A. polyanthum) towards multi-factorial drug resistant cancer cell lines. BMC Complement Altern Med. 2014;14: 340-347.
Bonina F, Lanza M, Montenegro L, et. al. Flavonoids as potential protective agents against photo-oxidative skin damage. Int J Pharm. 1996;145:87-94.
Skorek M, Jurczyk K, Sajewicz M, Kowalska T. Thin-layer chromatographic identification of flavonoids and phenolic acids contained in cosmetic raw materials. J Liq Chromatograph Rel Tech. 2016;39: 286-291.
Jiang L, Zhang Q, Ren H, et al. Dihydromyricetin enhances the chemo-sensivity of nedaplatin via regulation of the p53/Bcl-2 pathway in hepatocellular carcinoma cells. Plos One. 2015;10(4):e0124994.
Nishimura R, Tabata K, Arakawa M, et al. Isobavachalcone, a chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma. Biol Pharm Bull. 2007;30:1878-1883.
Neves MP, Cidade H, Pinto M, et al. Prenylated derivatives of baicalein and 3,7-dihydroxyflavone: synthesis and study of their effects on tumor cell lines growth, cell cycle and apoptosis. Eur J Med Chem. 2011;46:2562-2574.
Hisanaga A, Mukai R, Sakao K, Terao J, Hou D-X. Anti-inflammatory effects and molecular mechanisms of 8-prenyl quercetin. Mol Nutr Food Res. 2016;60(5):1020-1032.
Mukai M, Fujikura Y, Murota K, et al. Prenylation exhances quercetin uptake and reduces efflux in Caco-2 cells and enhances tissue accumulation in mice fed long-term. J Nutr. 2013;143(10):1558-1564.
Gao A-M, Ke Z-P, Shi F, Sun G-C, Chen H. Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. Chem Biol Interact. 2013;206(1):100-108.
Jakubowicz-Gil J, Paduch R, Piersiak T, Głowniak K, Gawron A, Kandefer-Szerszeń M. The effect of quercetin on proapoptotic activity of cisplatin in HeLa cells. Biochem Pharmacol. 2005;69:1343-1350.
Krajnović T, Kalucrossed D, Signerović GN, Wessjohann LA, Mijatović S, Masimović-Ivanić D. Versatile antitumor potential of isoxanthohumol: enhancement of paclitaxel activity in vivo. Pharmacol Res. 2016;105:62-73.
Zhang FY, Du GJ, Zhang CL, Lu WL, Liang W. Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein. Pharm Res. 2009;26(4):914-925.
Jakubowicz-Gil J, Langner E, Rzeski W. Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells. Pharmacol Rep. 2011;63(2):403-416.
Borska S, Sopel M, Chmielewska M, Zabel, Dzegiel P. Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules. 2015;15(2):857-870.
Staedler D, Idrizi E, Kenzaoui BH, Juillerat-Jeanneret L. Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother Pharmacol. 2011;68(5):1161-1172.
Silva FC, Bramatti, Toledo AG, Salles FM, Itnose AM, Marek CB. Antihyperglycemic effect of quercetin in ovariectomized rats treated with tamoxifen. J Med Food. 2017; 20(3):235-242.
Tu S-H, Ho C-T, Liu M-F, et al. Luteolin sensitises drug-resistant human breast cancer cells to tamoxifen via the inhibition of cyclin E2 expression. Food Chem. 2013;141(2): 1553-1561.
Zhang H, Zhong X, Zhang X, Shang D, Zhou Y, Zhang C. Enhanced anticancer effect of ABT-737 in combination with naringenin on gastric cancer cells. Exp Ther Med. 2016;11(2):669-673.
Su Y-K, Huang W-C, Lee W-H, et al. Methoxyphenyl chalcone sensitizes aggressive epithelial cancer to cisplatin through apoptosis induction and cancer stem cell eradication. Tumor Biol. 2017;39(5):1010428317691689.
Erdogan S, Turkekul K, Serttas R, Erdogan Z. The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy. Biomed Pharmacol. 2017;88:210-217.
Kim EH, Jang HJ, Shin D, Baek SH, Roh J-L. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer. Apoptosis. 2016;21(11):1265-1278.
Hou X, Bai X, Gou X, et al. 3’,4’,5’,5,7-Pentamethoxyflavone sensitizes cisplatin-resistant A549 cells to cisplatin by inhibition of Nrf2 pathway. Mol Cells. 2015;38(5): 396-401.
Luo H, Daddysman MK, Rankin GO, Jiang BH, Chen YC. Kaempferol enhances cisplatin’s effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc. Cancer Cell Int. 2010;10: 16.
Sato Y, Sasaki N, Saito M, Endo N, Kugawa F, Ueno A. Luteolin attenuates doxorubicin-induced cytotoxicity to MCF-7 human breast cancer cells. Biol Pharm Bull. 2015;38(5):703-709.
Xu Y, Xin Y, Diao Y, et al. Synergistic effects of apigenin and paclitaxel on apoptosis of cancer cells. PLoS ONE. 2011;6(12):e29169.
Hao T, Ling Y, Wu M, et al. Enhanced oral bioavailability of docetaxel in rats combined with myricetin: in situ and in vivo evidences. Eur J Pharm Sci. 2017;101:71-79.
He F, Wang Q, Zheng XL, et al. Wogonin potentiates cisplatin-induced cancer cel apoptosis through accumulation of intracellular reactive oxygen species. Oncol Rep. 2012;28(2):601-605.
Darwish HA, Arab HH, Abdelsalam RM. Chrisin alleviates testicular dysfunction in adjuvant arthritic rats via suppression of inflammation and apoptosis; comparison with celecoxib. Toxicol Appl Pharmacol. 2014;279(2):129-140.
Han Y, Yu H, Wang J, Ren Y, Su X, Shi Y. Quercetin alleviates myocyte toxic and sensitizes anti-leukemic effect of adriamycin. Hamatolohy. 2015;20(5):276-283.
Jakubowicz-Gil J, Langner E, Bądziul D, Wertel I, Rzeski W. Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. Neurotox Res. 2014;26(1):64-77.
Wang G, Zhang J, Liu L, Sharma S, Dong Q. Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS ONE. 2012; 7(12):e51764.
Chakrabarti M, Ray SK. Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. Apoptosis. 2016;21:312-328.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
